Please wait a minute...

中国生物工程杂志

China Biotechnology
China Biotechnology  2007, Vol. 27 Issue (4): 115-119    DOI:
    
Glucagon-Like PeptideⅠand targeted differentiation of stem cells
Download: HTML   PDF(381KB) HTML
Export: BibTeX | EndNote (RIS)      

Abstract  

Abstract:Diabetes mellitus with the increasing prevalence has become one of the diseases which threaten the heath Diabetes mellitus has become one of the diseases which threaten the heath of human being in the 21st century.A goal of research in diabetes is to find a way to increase the number of functional insulin-producing cells. Islet transplantation has been considered to be the most effective approach to cure type Ⅰ and part of type Ⅱ diabetes mellitus.This approach, however, is severely limited by an inadequate supply of donor islets available for transplantation.Moreover, recent progress of stem cells research has shown that stem cells may act as a new source of islet transplantation in diabetes mellitus treatment. Recent evidence indicates that Glucagon-Like PeptideⅠ(GLP-1) plays a very important role in targeted differentiation of stem cells into Insulin-Producing Cells and pancreatic development. GLP-1 is an intestine-derived insulinotropic hormone that stimulates glucose dependent insulin production and secretion. GLP-1 can induce differentiation of stem cells into insulin-producing cells, which is achieved by up regulation of PDX-1 expression.PDX-1 is a transcription factor critical for pancreatic development and endocrine cell neogenesis and a marker for pancreatic stem cells. These new findings suggest an approach to create Insulin-Producing cells in vitro by expanding stem/progenitor cells and then to convert them into Insulin-Producing cells by treatment with GLP-1. Thus GLP-1 may be a means by which to create Insulin-Producing cells ex vivo for transplantation into patients with insulinopenic type Ⅰ diabetes and severe forms of type Ⅱ diabetes. This article reviews recent progress about GLP-1 and targeted differentiation of stem cells induced by GLP-1.



Key wordsGlucagon-Like PeptideⅠ(GLP-1)      stem cells      diabetes mellitus     
Received: 22 January 2007      Published: 25 April 2007
Cite this article:

. Glucagon-Like PeptideⅠand targeted differentiation of stem cells. China Biotechnology, 2007, 27(4): 115-119.

URL:

https://manu60.magtech.com.cn/biotech/     OR     https://manu60.magtech.com.cn/biotech/Y2007/V27/I4/115

[1] QIAN Yu,DING Xiao-yu,LIU Zhi-qiang,YUAN Zeng-qiang. An Efficient Monoclonal Establishment Method of Genetically Modified Human Pluripotent Stem Cells[J]. China Biotechnology, 2021, 41(8): 33-41.
[2] LI Kai-xiu,SI Wei. Progress in the Treatment of Inflammatory Bowel Diseases by Exosomes Derived from Mesenchymal Stem Cells[J]. China Biotechnology, 2021, 41(7): 66-73.
[3] WANG Yu-xuan,CHEN Ting,ZHANG Yong-liang. Research Progress on the Biological Function of MiR-148[J]. China Biotechnology, 2021, 41(7): 74-80.
[4] ZHAO Jiu-mei,WANG Zhe,LI Xue-ying. Role of Signal Pathways and Related Factors Regulating Cartilage Formation in Bone Differentiation of Bone Marrow Mesenchymal Stem Cells[J]. China Biotechnology, 2021, 41(10): 62-72.
[5] CHEN Fei,WANG Xiao-bing,XU Zeng-hui,QIAN Qi-jun. Molecular Mechanism and Clinical Research Progress of Mesenchymal Stem Cells in the Treatment of Diabetes Mellitus[J]. China Biotechnology, 2020, 40(7): 59-69.
[6] DAI Qi-nan,ZHANG Jing-hong. Advances in Molecular Mechanisms Related to Tumor Multi-drug Resistance, Autophagy, DNA Repair and Tumor Stem Cells[J]. China Biotechnology, 2020, 40(4): 69-77.
[7] YUAN Ya-kun,LIU Guang-yang,LIU Yong-jun,XIE Ya-fang,WU Hao. Comparison of Research and Clinical Transformation on Mesenchymal Stem Cells between China and the US[J]. China Biotechnology, 2020, 40(4): 97-107.
[8] CHEN Li-jun,QU Jing-jing,XIANG Charlie. Therapeutic Potentials, Clinical Studies, and Application Prospects of Mesenchymal Stem Cells in 2019 Novel Coronavirus (COVID-19)[J]. China Biotechnology, 2020, 40(11): 43-55.
[9] QIU Dan-dan,LU Cai-xia,DAI Jie-jie. Application of Hepatocyte-like Cells Derived from Induced Pluripotent Stem Cells in HCV Infection Model[J]. China Biotechnology, 2020, 40(11): 67-72.
[10] ZHU Yongzhao,TAO Jin,REN Meng-meng,XIONG Ran,HE Ya-qin,ZHOU Yu,LU Zhen-hui,DU Yong,YANG Zhi-hong. Autophagy Protects Against Apoptosis of Human Placental Mesenchymal Stem Cells of Fetal Origin Induced by Tumor Necrosis Fator-α[J]. China Biotechnology, 2019, 39(9): 62-67.
[11] Yue-lei FAN,Jiao LU,Da-ming CHEN,Kai-yun MAO. Strategies for Stem Cell Patent Evaluation and Patent Transfer and Transformation[J]. China Biotechnology, 2019, 39(1): 99-106.
[12] Wen-wen SHI,Lei ZHANG. Current Research of Micro Mechanical Environmental Effects on Mesenchymal Stem Cells’ Differentiation[J]. China Biotechnology, 2018, 38(8): 76-83.
[13] Yan ZHENG,Huan YAO,Ke YANG. SFRP5 Inhibites Osteogenic Differentiation of Human Umbilical Cord-derived Mesenchymal Stem Cells Induced by BMP9[J]. China Biotechnology, 2018, 38(7): 7-13.
[14] Ming-ming HAN,Yu-ping LUO. Establishment and Identification of Endogenous CD133 + Cell Tracer Mouse Model[J]. China Biotechnology, 2018, 38(6): 58-62.
[15] Ya-nan LIU,Li LU,Xue-xi WANG,Yong-jie WU,Xia LIU. Research Pogress of Adipose Derived Stem Cells on Nerve Injury Repair[J]. China Biotechnology, 2018, 38(3): 70-75.